Financial Performance - The company's operating revenue for Q3 2023 was CNY 70,466,638.51, representing a year-on-year increase of 65.52%[5] - The net profit attributable to shareholders for Q3 2023 was CNY 4,408,843.35, an increase of CNY 5,228,735.1 compared to the same period last year[11] - The net profit attributable to shareholders for the year-to-date period was CNY 3,297,845.75, up CNY 6,889,935.67 year-on-year[11] - The basic and diluted earnings per share for Q3 2023 were both CNY 0.05, compared to CNY 0.04 for the same period last year[6] - The net profit attributable to shareholders, excluding non-recurring gains and losses, for the current period is ¥1,000,637.03, an increase of ¥3,984,744.25 compared to the same period last year[12] - The net profit attributable to shareholders, excluding non-recurring gains and losses, for the year-to-date period is -¥6,369,408.34, an increase of ¥6,091,445.66 compared to the same period last year[12] - In Q3 2023, the company reported a net profit of CNY 3,391,715.57, a significant recovery from a net loss of CNY 3,597,401.60 in the same period last year[26] - The total profit for Q3 2023 was CNY 2,630,915.73, compared to a total loss of CNY 4,171,961.79 in Q3 2022, indicating a turnaround in financial performance[26] - The company's operating profit for Q3 2023 was CNY 2,414,293.84, a recovery from an operating loss of CNY 4,458,677.46 in the previous year[26] Cash Flow and Liquidity - The company reported cash flows from operating activities of CNY 10,667,195.08 for the year-to-date period[6] - The net cash flow from operating activities for the current period is ¥10,667,195.08, an increase of ¥45,002,005.89 compared to the same period last year, primarily due to improved collection of receivables and reduced material procurement expenditures[12] - The cash flow from operating activities for the first nine months of 2023 was CNY 10,667,195.08, a significant improvement from a negative cash flow of CNY 34,334,810.81 in the same period of 2022[29] - The company's cash and cash equivalents decreased to ¥147,853,156.24 from ¥198,253,632.14, a decline of 25.4%[20] - The company’s cash and cash equivalents at the end of Q3 2023 stood at CNY 147,853,156.24, compared to CNY 126,065,735.02 at the end of Q3 2022, reflecting improved liquidity[30] Research and Development - Research and development expenses totaled CNY 11,516,536.33 for Q3 2023, accounting for 16.34% of operating revenue, a decrease of 9.40 percentage points year-on-year[6] - Research and development expenses for the first three quarters of 2023 amounted to ¥34,762,082.95, slightly increasing from ¥33,373,140.73 in 2022[25] Assets and Liabilities - Total assets at the end of Q3 2023 were CNY 931,431,601.12, reflecting a 3.18% increase from the end of the previous year[6] - The company's total assets as of September 30, 2023, were ¥931,431,601.12, compared to ¥902,683,287.61 at the end of 2022, indicating growth of 3.2%[22] - Current assets totaled ¥790,878,860.23 as of September 30, 2023, down from ¥812,134,833.48 at the end of 2022, a decrease of 2.5%[20] - The company's total liabilities increased to ¥83,484,033.87 as of September 30, 2023, compared to ¥58,526,453.43 at the end of 2022, representing a rise of 42.5%[21] Shareholder Information - The top ten shareholders hold a total of 6,108 shares, with the largest shareholder, Liu Jianqiang, holding 12,810,000 shares, representing 14.54% of the total[14] - The second-largest shareholder, Zhongxin Suzhou Industrial Park Venture Capital Co., Ltd., holds 8,965,203 shares, accounting for 10.17%[15] Strategic Focus - The company attributed revenue growth to the successful implementation of new products and technologies, as well as improved customer satisfaction and new client acquisition[11] - The company has improved its cost accounting model, leading to more effective cost control and a stabilization of gross profit margins[12] - The company has implemented a strategy to optimize cost management and enhance operational profitability through improved budgeting systems[12] - The company is focused on market expansion and new product development as part of its growth strategy moving forward[12] Performance Metrics - The weighted average return on equity for Q3 2023 was 0.52%, an increase of 0.61 percentage points compared to the same period last year[6] - Basic and diluted earnings per share for Q3 2023 were both CNY 0.04, recovering from a loss of CNY 0.04 per share in Q3 2022[27] - The company experienced a decrease in revenue from sales of goods and services, totaling CNY 163,371,865.08 in the first nine months of 2023, down from CNY 173,395,683.98 in the same period of 2022[29]

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688607 证券简称：康众医疗 公告编号：2023-037 江苏康众数字医疗科技股份有限公司 关于召开 2023 年第二次临时股东大会的通知 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年第二次临时股东大会 召开日期时间：2023 年 11 月 13 日 14:00 点 00 分 召开地点：江苏省苏州市工业园区星湖街 218 号生物纳米园 B3 楼 5 层 501 室公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 11 月 13 日 至 2023 年 11 月 13 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2023年11月13日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和 ...

证券代码：688607 证券简称：康众医疗 公告编号：2023-036 江苏康众数字医疗科技股份有限公司 关于非独立董事辞职暨选举非独立董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、关于非独立董事辞职的情况说明 二、关于补选非独立董事的情况说明 为完善公司治理结构，保证公司董事会的规范运作，根据《公司章程》等相 关规定，公司于2023年10月27日召开第二届董事会第十三次会议，审议通过了《关 于选举非独立董事的议案》，同意推选凌骏先生为公司第二届董事会非独立董事 候选人（简历详见附件），该事项尚需提交公司2023年第二次临时股东大会审议。 凌骏先生任期自2023年第二次临时股东大会审议通过之日起至第二届董事会任 期届满日止。 江苏康众数字医疗科技股份有限公司（以下简称"公司"）董事会近期收到 公司非独立董事何鲲先生的辞职报告，何鲲先生因个人原因申请辞去公司第二届 董事会董事职务。根据《公司法》《公司章程》等相关规定及何鲲先生辞职报告 说明，何鲲先生辞职将导致公司董事会成员人数低于《公司章程》规定人数，为 ...

江苏康众数字医疗科技股份有限公司 独立董事关于第二届董事会第十三次会议相关事项的 经过对非独立董事候选人凌骏先生的背景及工作经历了解，我们认为其符合 相关法律、行政法规、规范性文件对董事任职资格的要求，不存在《公司法》、 《公司章程》规定的不得担任公司董事的情形，未受到中国证监会的行政处罚或 交易所惩戒，不存在上海证券交易所认定不适合担任上市公司董事的其他情形。 公司非独立董事候选人的提名、表决程序符合《公司法》等法律法规及《公司章 程》的相关规定，并已征得被提名人本人同意，表决结果合法、有效。 基于上述，我们同意凌骏先生为公司第二届董事会非独立董事候选人，并同 意提交股东大会审议。 独立董事：王强、王美琪、蒋新华 独立意见 根据中国证监会《上市公司独立董事管理办法》等法律法规和《公司章程》 《独立董事工作制度》等公司内控制度的有关规定，我们作为江苏康众数字医疗 科技股份有限公司（以下简称"公司"）的独立董事，基于独立、审慎、客观的 立场，经审慎分析，对公司第二届董事会第十三次会议审议的相关事项进行认真 审核并发表如下独立意见： 一、关于选举非独立董事的独立意见 ...

与会监事就如下议案进行了认真审议，并表决通过以下事项： 证券代码：688607 证券简称：康众医疗 公告编号：2023-038 江苏康众数字医疗科技股份有限公司 第二届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 江苏康众数字医疗科技股份有限公司（以下简称"公司"）第二届监事会第 十三次会议于 2023 年 10 月 27 日上午 11:00 在公司会议室以现场结合通讯表决 方式召开，会议通知于 2023 年 10 月 17 日以电子邮件方式送达全体监事。本次 会议由监事会主席郭涛先生主持，会议应出席监事 3 名，实际出席监事 3 名。本 次会议的召集和召开程序符合有关法律、行政法规、部门规章、规范性文件和公 司章程的规定。 二、监事会会议审议情况 1.审议通过《关于公司＜2023 年第三季度报告＞的议案》 经审议，与会监事认为：公司董事会编制的《2023 年第三季度报告》内容 真实、准确、完整，不存在虚假记载、误导性陈述、重大遗漏。 表决结果：同意 3 票，反对 0 ...

证券代码：688607 证券简称：康众医疗 公告编号：2023-035 江苏康众数字医疗科技股份有限公司 2023 年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2023 年 9 月 14 日 （二） 股东大会召开的地点：苏州工业园区星湖街 218 号生物纳米园 B3 楼 501 室公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 9 | | --- | --- | | 普通股股东人数 | 9 | | 2、出席会议的股东所持有的表决权数量 | 33,892,631 | | 普通股股东所持有表决权数量 | 33,892,631 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 38.4580 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | ...

法律意见书 北京市中伦律师事务所 2023 年第一次临时股东大会的 法律意见书 致：江苏康众数字医疗科技股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受江苏康众数字医疗科技股 份有限公司（以下简称"公司"）的委托，就公司 2023 年第一次临时股东大会 （以下简称"本次股东大会"）召开的有关事宜，根据《中华人民共和国公司法》 （以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、《上 市公司股东大会规则（2022 年修订）》（以下简称《股东大会规则》）和上海证券 交易所发布的《上海证券交易所上市公司自律监管指引第 1 号——规范运作 （2023 年 8 月修订）》等现行有效的法律、法规、规范性文件及《江苏康众数字 医疗科技股份有限公司章程》（以下简称《公司章程》）、《江苏康众数字医疗科技 股份有限公司股东大会议事规则》（以下简称《股东大会议事规则》）的有关规定， 出具本法律意见书。 为出具本法律意见书，本所律师审查了公司本次股东大会的有关文件和材料。 本所律师得到公司如下保证，即其已提供了本所律师认为出具本法律意见书所必 需的材料，所提供的原始材料、副本、复印件等材料、口头证言均符 ...

江苏康众数字医疗科技股份有限公司 2023 年第一次临时股东大会会议资料 证券代码：688607 证券简称：康众医疗 江苏康众数字医疗科技股份有限公司 2023 年第一次临时股东大会会议资料 二〇二三年九月 1 / 13 | 2023 | 年第一次临时股东大会会议须知 3 | | --- | --- | | 2023 | 年第一次临时股东大会会议议程 5 | | 2023 | 年第一次临时股东大会议案 7 | | | 关于修订《公司章程》的议案 8 | | | 关于修订《股东大会议事规则》的议案 9 | | | 关于修订《董事会议事规则》的议案 10 | | | 关于修订《监事会议事规则》的议案 11 | | | 关于修订《独立董事工作制度》的议案 12 | | | 关于修订《累积投票制实施细则》的议案 13 | 江苏康众数字医疗科技股份有限公司 2023 年第一次临时股东大会会议资料 江苏康众数字医疗科技股份有限公司 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，请出 席大会的股东或其代理人或其他出席者准时到达会场签到确认参会资格。并请按 规定出示证券账户卡、身份证明文件或营业执照复印件、授 ...

二、保荐机构和保荐代表人发现的问题及整改情况 2023 年上半年度，保荐机构和保荐代表人未发现康众医疗存在重大问题。 中信证券股份有限公司 关于江苏康众数字医疗科技股份有限公司 2023 年半年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"或"保荐人"）作 为江苏康众数字医疗科技股份有限公司（以下简称"康众医疗"或"公司"）首次公开 发行股票并在科创板上市项目的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则》等相关规定，负责康众医疗上市后的持续督导工作， 并出具本持续督导半年度跟踪报告。 1 一、持续督导工作情况 序号 工作内容 实施情况 1 建立健全并有效执行持续督导工作制度，并针对具体 的持续督导工作制定相应的工作计划。 保荐机构已建立健全并有效执行了持 续督导制度，并制定了相应的工作计 划。 2 根据中国证券监督管理委员会（以下简称"中国证监 会"）相关规定，在持续督导工作开始前，与上市公司 签署持续督导协议，明确双方在持续督导期间的权利 义务，并报上海证券交易所备案。 保荐机构已与康众医疗签订承销及保 荐协议，该协议明确了双方在持续督 ...

Financial Performance - The company reported a revenue of RMB 200 million for the first half of 2023, representing a year-on-year increase of 15%[14]. - The company's operating revenue for the first half of 2023 was ¥110,938,686.53, an increase of 10.17% compared to the same period last year[21]. - The net profit attributable to shareholders for the same period was -¥1,110,997.60, an improvement of ¥1,661,200.54 year-on-year[22]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion in the first half of 2023, representing a 25% year-over-year growth[117]. - The company reported a total revenue of 45,241,432.20 RMB for the first half of 2023, with a net profit of 5,790,608.44 RMB, indicating a significant performance in the market[54]. - The company provided a positive outlook for the second half of 2023, projecting a revenue increase of 20% to $600 million[132]. - The company has set a performance guidance of $1.2 billion in total revenue for the full year 2023, reflecting a 22% growth target[132]. User Engagement - User data indicates that the number of active users of the company's digital medical products reached 1.5 million, up 20% compared to the same period last year[14]. - User data showed a growth in active users, reaching 5 million, which is a 15% increase compared to the previous year[118]. - Customer satisfaction ratings improved to 90%, indicating strong user engagement and loyalty[132]. Research and Development - Research and development expenses increased by 25% to RMB 30 million, focusing on digital X-ray imaging technology advancements[14]. - The company's R&D expenditure accounted for 20.95% of operating revenue, a decrease of 1.31 percentage points year-on-year[21]. - The company has made significant progress in R&D, with a total of 15 new intellectual property rights obtained in the first half of 2023[49]. - The company is investing heavily in R&D, with a budget increase of 30% to enhance product innovation and technology development[117]. - The company is focusing on the development of digital X-ray flat panel detectors and expanding into other key components like collimators and high-voltage generators[68]. Market Expansion - The company plans to expand its market presence in Southeast Asia, targeting a 5% market share by the end of 2024[14]. - The company is focusing on expanding its market presence in the dental and industrial sectors, driven by increasing demand and domestic substitution trends[44]. - Market expansion plans include entering three new international markets by Q4 2023, aiming for a 10% market share in each[118]. - The company is expanding its market presence in Asia, targeting a 30% increase in market share by the end of 2024[132]. Product Development - A new digital radiography product is set to launch in Q3 2023, anticipated to contribute an additional RMB 50 million in revenue[14]. - The company has launched several new products, including wireless dynamic flat panel detectors and digital intraoral sensors, to meet growing market demands[46]. - New product launches are expected to contribute an additional 300 million in revenue by the end of the year[118]. - The company is focusing on the customization of unconventional flat panel detectors and the application of advanced sensor technologies, indicating a strong commitment to innovation[59]. Financial Management - The gross profit margin improved to 45%, up from 40% in the previous year, reflecting better cost management[14]. - The company has adjusted its procurement strategy to reduce material purchase expenditures, contributing to improved cash flow[22]. - Operating costs increased by 4.42% to ¥70,669,701.59, attributed to increased business volume and effective cost control measures[85]. - The company is focusing on optimizing cost control and improving profitability through strategic collaborations and supply chain management[74]. Risks and Challenges - The management highlighted potential risks related to supply chain disruptions and regulatory changes impacting future operations[14]. - The company faces risks related to talent retention, core technology leakage, and intensified market competition in the digital X-ray flat panel detector industry[75][80]. Corporate Governance - The management emphasized the importance of maintaining strong corporate governance and compliance with regulatory requirements during the growth phase[118]. - The company is committed to maintaining investor trust through rigorous adherence to its promises and transparent reporting practices[130]. Shareholder Information - The company reported a total of 88,129,027 shares outstanding, with 65,407,415 shares being unrestricted, representing 74.22% of total shares[153]. - The number of shareholders reached 5,588 by the end of the reporting period[158]. - The top ten shareholders include Xuan Yuan Private Fund Management with a total of 2,504,067 shares held through both ordinary and credit accounts[159]. Cash Flow and Investments - The net cash flow from operating activities was -¥3,324,941.11, an increase of ¥16,097,549.62 compared to the previous year[22]. - Cash and cash equivalents at the end of the period amounted to 306,986,138.88 CNY, representing 33.59% of total assets, an increase of 54.85% from the previous year[91]. - The company has approved the use of up to RMB 300 million of idle raised funds for cash management, with a rolling usage period until the annual board meeting in 2023[146]. Compliance and Regulations - The company has committed to ensuring fair pricing in related transactions to protect the interests of all shareholders[136]. - The company will comply with relevant laws and regulations regarding share transfers and commitments[116].